Carga de enfermedad. Cálculo del riesgo cardiovascular y objetivos terapéuticos

Marco-Benedí V. ; Jarauta Simón E. (Universidad de Zaragoza) ; Laclaustra Gimeno M. (Universidad de Zaragoza) ; Civeira Murillo F. (Universidad de Zaragoza)

Resumen: Therapeutic intervention should be determined by the risk of developing atheromatous cardiovascular disease (CVD). The higher the risk, the more intense the action should be. This is the reason for the stratification of patient risk. In primary prevention, the two main guidelines used, the American Heart Association and the American College of Cardiology (ACC/AHA) use the Pooled cohort equations (PCE) and the guidelines of the European societies use the SCORE tables. The PCE calculates the risk of fatal and non-fatal CVD, and the SCORE calculates risk of fatal CVD only. In young people, it is useful to consider the lifetime risk calculation. The Spanish Society of Arteriosclerosis (SEA) recommends the SCORE system in Spain. SCORE and PCE calculate the risk for people up to 70 and 75 years of age. Prediction and potentials are available for 80 years of age and above, with the data available being much more scarce. Risk stratification in secondary prevention may be useful to identify the subgroup of patients who may benefit from more intensive treatment. Imaging tests, especially coronary calcium scans and vascular ultrasound, can help to better the profile risk. European guidelines identify LDL cholesterol as a therapeutic target. They recommend initiating treatment with statins, and increasing dose and potency until targets are achieved, and then to treatment with potent statins at a maximum tolerated dose, and ezetimibe if targets are not achieved. As a third step, PCSK9 inhibitors are indicated. They set very ambitious targets, as low as 40 mg/dL in those subjects with recurrences before two years of CVD despite high-intensity statin therapy, and below 55 mg/dL for all very high-risk subjects. © 2021 Sociedad Española de Arteriosclerosis

Idioma: Español

DOI: 10.1016/j.arteri.2020.12.006

Año: 2021

Publicado en: Clinica e Investigacion en Arteriosclerosis 33 (2021), 10-17
ISSN: 0214-9168

Factor impacto CITESCORE: 2.1 - Medicine (Q3)

Factor impacto SCIMAGO: 0.325 - Pharmacology (medical) (Q3) - Cardiology and Cardiovascular Medicine (Q3)

Tipo y forma: Article (Published version)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)